English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduLearn how scientists at St. Jude are leading research to improve CAR T-cell therapy for osteosarcoma by enhancing chemokine homing.
Tag: chimeric antigen receptor
Novel bispecific design improves CAR T–cell immunotherapy for childhood leukemia
Findings from St. Jude Children’s Research Hospital showed a novel dual targeting approach, where a single molecule can recognize two potential cancer-related proteins, is more effective than the single targeting approach, preventing immune escape.
CAR-T immune therapy attacks ovarian cancer in mice with a single dose
CAR-T immune therapies could be effective against solid tumors if the right targets are identified, a new study led by University of Illinois Urbana-Champaign researchers suggests. The researchers successfully deployed CAR-T in a mouse model of ovarian cancer, a type of aggressive, solid-tumor cancer that has eluded such therapies until now.
New CAR T-Cell Strategy Highly Effective Against Small Cell Lung Cancer in Preclinical Study
A new approach to chimeric antigen receptor T-cell (CAR T) therapy has shown great promise against small cell lung cancer (SCLC) in a preclinical study. The findings cover new ground in our understanding of how CAR T can be employed against solid-tumor cancers, and provide support for further studies in cancer patients.
Penn Medicine Developed CAR T Cell Therapy Wins Third FDA Approval
The U.S. Food and Drug Administration (FDA) has expanded its approval for a personalized cellular therapy developed at the University of Pennsylvania’s Abramson Cancer Center, this time for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. The accelerated approval was granted today to Novartis for the chimeric antigen receptor (CAR) T-cell therapy Kymriah® (tisagenlecleucel), making it the third indication for the nation’s first personalized cellular therapy for cancer. It remains the only CAR-T cell therapy approved for both adult and pediatric patients.
Penn Medicine and Children’s Hospital of Philadelphia Announce Partnership with Costa Rica for CAR T Cell Therapy
Penn Medicine and Children’s Hospital of Philadelphia (CHOP), who together pioneered the research and development of the world’s first personalized cellular therapy for cancer — also known as CAR T cell therapy — have announced plans with Costa Rica’s CCSS, or the Caja Costarricense de Seguro Social (Social Security Program), to facilitate CAR T research in Costa Rica.
T Cell Therapy, Gut Microbiome, Tumorigenicity, and More Featured in September 2020 Toxicological Sciences
Toxicological Sciences features leading research in toxicology in the areas of biomarkers, environmental toxicology, and more in the September 2020 issue.
Cancer Immunotherapy Target Helps Fight Solid Tumors
Yvonne Chen engineers immune cells to target their most evasive enemy: cancer. New cancer immunotherapies generate immune cells that are effective killers of blood cancers, but they have a hard time with solid tumors.